TaxesAreTheft (@TaxesAreTheft) sur getquin

1Mo·

I assume that if $LLY (+1,78 %) and $NOVO B (-17,74 %) do not follow suit $VKTX (+1,85 %) will become the new market leader.

It could even be that Viking will be the only provider of an effective and well-tolerated weight loss pill for a long time.

Viking is very likely to bring the next two really big blockbuster drugs onto the market. Since the market has been waiting for such blockbusters for a long time, the valuation will be correspondingly high.

Should the share price fall again, take a look at all the GLP-1 pipelines and Viking.

TaxesAreTheft

@TaxesAreTheft

1Mo·

VK2735 with excellent results

VK2735 (weight loss pill) from Viking Therapeutics $VKTX (+1,85 %) delivers. At a dose of 100mg, testers lost an average of 8.2% of their body weight over 28 days. VK2735 is not only very effective but also well tolerated.

10 Commentaires

András A.@Spinat

1Mo

The first is an SC injection, phase 2 study, the second is orally administered product and only the phase 1 study (phase 2 planned). Why do you think these products will replace the products already on the market?

•

Voir toutes les 8 autres réponses

Gomerdoc@Gomerdoc

1Mo

However, Phase 1+2 are IRRELEVANT for approval and reimbursement by global health insurance companies. And also with regard to the actual efficacy or superiority to a comparative therapy. Incidentally, in case of doubt, a clique like Viking is simply swallowed up. These little things often fail in Phase 3 trials, and only then do things get really expensive....

•